Classification of current anticancer immunotherapies
Autor(es) : 
Galluzzi, L. (Lorenzo)
Vacchelli, E. (Erika)
Bravo-San-Pedro, J.M. (José-Manuel)
Buque, A. (Aitziber)
Senovilla, L. (Laura)
Baracco, E.E. (Elisa Elena)
Bloy, N. (Norma)
Castoldi, F. (Francesca)
Abastado, J.P. (Jean-Pierre)
Agostinis, P. (Patrizia)
Apte, R.N. (Ron N.)
Aranda, F. (Fernando)
Ayyoub, M. (Maha)
Beckhove, P. (Philipp)
Blay, J.Y. (Jean-Yves)
Bracci, L. (Laura)
Caignard, A. (Anne)
Castelli, C. (Chiara)
Cavallo, F. (Federica)
Celis, E. (Esteban)
Cerundolo, V. (Vincenzo)
Clayton, A. (Aled)
Colombo, M.P. (Mario P.)
Coussens, L. (Lisa)
Dhodapkar, M.V. (Madhav V.)
Eggermont, A.M. (Alexander M.)
Fearon, D.T. (Douglas T.)
Fridman, W.H. (Wolf H.)
Fučíková, J. (Jitka)
Gabrilovich, D.I. (Dmitry I.)
Galon, J. (Jerome)
Garg, A. (Abhishek)
Ghiringhelli, F. (François)
Giaccone, G. (Giuseppe)
Gilboa, E. (Eli)
Gnjatic, S. (Sacha)
Hoos, A. (Axel)
Hosmalin, A. (Anne)
Jäger, D. (Dirk)
Kalinski, P. (Pawel)
Kärre, K. (Klas)
Kepp, O. (Oliver)
Kiessling, R. (Rolf)
Kirkwood, J.M. (John M.)
Klein, E. (Eva)
Knuth, A. (Alexander)
Lewis, C.E. (Claire E.)
Liblau, R. (Roland)
Lotze, M.T. (Michael T.)
Lugli, E. (Enrico)
Mach, J.P. (Jean-Pierre)
Mattei, F. (Fabrizio)
Mavilio, D. (Domenico)
Melero, I. (Ignacio)
Melief, C.J. (Cornelis J.)
Mittendorf, E.A. (Elizabeth A.)
Moretta, L. (Lorenzo)
Odunsi, A. (Adekunke)
Okada, H. (Hideho)
Palucka, A.K. (Anna Karolina)
Peter, M.E. (Marcus E.)
Pienta, K.J. (Kenneth J.)
Porgador A. (Ángel), A. (Angel)
Prendergast, G.C. (George C.)
Rabinovich, G.A. (Gabriel A.)
Restifo, N.P. (Nicholas P.)
Rizvi, N. (Naiyer)
Sautès-Fridman, C. (Catherine)
Schreiber, H. (Hans)
Seliger, B. (Barbara)
Shiku, H. (Hiroshi)
Silva-Santos, B. (Bruno)
Smyth, M.J. (Mark J.)
Speiser, D.E. (Daniel E.)
Spisek, R. (Radek)
Srivastava, P.K. (Pramod K.)
Talmadge, J.E. (James E.)
Tartour, E. (Eric)
Van-Der-Burg, S.H. (Sjoerd H.)
Van-Den-Eynde, B.J. (Benoît J.)
Vile, R.G. (Richard G.)
Wagner, H. (Hermann)
Weber, J.S. (Jeffrey S.)
Whiteside, T.L. (Theresa L.)
Wolchok, J.D. (Jedd D.)
Zitvogel, L. (Laurence)
Zou, W. (Weiping)
Kroemer, G. (Guido)
Palabras clave : 
Adoptive cell transfer
Checkpoint blockers
Dendritic cell-based interventions
DNA-based vaccines
Immunostimulatory cytokines
Peptide-based vaccines
Oncolytic viruses
Toll-like receptor agonists
Fecha de publicación: 
2014
Editorial : 
Impact Journals
ISSN: 
1949-2553
Cita: 
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014 Dec;5(24):12472-12508
Resumen
During the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical studies. Immunotherapies may be subdivided into “passive” and “active” based on their ability to engage the host immune system against cancer. Since the anticancer activity of most passive immunotherapeutics (including tumor-targeting monoclonal antibodies) also relies on the host immune system, this classification does not properly reflect the complexity of the drug-host-tumor interaction. Alternatively, anticancer immunotherapeutics can be classified according to their antigen specificity. While some immunotherapies specifically target one (or a few) defined tumor-associated antigen(s), others operate in a relatively non-specific manner and boost natural or therapy-elicited anticancer immune responses of unknown and often broad specificity. Here, we propose a critical, integrated classification of anticancer immunotherapies and discuss the clinical relevance of these approaches.

Ficheros en este registro:
Fichero: 
oncotarget-05-12472.pdf
Descripción: 
Tamaño: 
1,35 MB
Formato: 
Adobe PDF


Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.